SECTORAL ASSET MANAGEMENT INC
13F Reported Value
ⓘ$120.7M
Holdings
77
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
SECTORAL ASSET MANAGEMENT INC disclosed 77 positions worth $120.7M in its Form 13F-HR for Q1 2026, led by $EVMN (Evommune, Inc.) at 11.2% of the equity portfolio, followed by $CTNM and $SI. During the quarter the fund opened 10 new positions and exited 7 — including a new stake in $IQV and a full exit from $AZN. The portfolio is most concentrated in Healthcare (96.4% of disclosed assets). All figures are sourced directly from SECTORAL ASSET MANAGEMENT INC’s Form 13F-HR filing with the SEC under CIK 1274413.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$13.5M589,005 sh - —
Quality
$9.5M727,587 sh - 46.5#1,652
Quality
$6.3M430,407 sh - 89.3
Quality
$5.8M6,354 sh - 72.8
Quality
$4.5M18,218 sh - 77.8
Quality
$4.1M27,490 sh - 66.8
Quality
$4.0M14,957 sh - 79.5
Quality
$3.5M9,210 sh - 76.6
Quality
$3.5M7,007 sh - 29.4
Quality
$3.4M19,668 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Evommune, Inc.$EVMN | — | $13.5M | 589,005 |
 Contineum Therapeutics, Inc.$CTNM | — | $9.5M | 727,587 |
 SHOULDER INNOVATIONS, INC.$SI | 46.5#1,652 | $6.3M | 430,407 |
 ELI LILLY & Co$LLY | 89.3 | $5.8M | 6,354 |
 JOHNSON & JOHNSON$JNJ | 72.8 | $4.5M | 18,218 |
 GILEAD SCIENCES, INC.$GILD | 77.8 | $4.1M | 27,490 |
 UNITEDHEALTH GROUP INC$UNH | 66.8 | $4.0M | 14,957 |
 AMGEN INC$AMGN | 79.5 | $3.5M | 9,210 |
 VERTEX PHARMACEUTICALS INC / MA$VRTX | 76.6 | $3.5M | 7,007 |
 INSMED Inc$INSM | 29.4 | $3.4M | 19,668 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of SECTORAL ASSET MANAGEMENT INC's 77 positions.
Showing top 10 of 77 holdings.
Sector Allocation
Healthcare
$116.4M
Technology
$4.3M
Full Holdings — SECTORAL ASSET MANAGEMENT INC (Q1 2026)
All 77 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $EVMN | Evommune, Inc. | $13.5M | 11.2% | +0% | — |
| 2 | $CTNM | Contineum Therapeutics, Inc. | $9.5M | 7.9% | -9% | — |
| 3 | $SI | SHOULDER INNOVATIONS, INC. | $6.3M | 5.2% | -13% | 46.5 |
| 4 | $LLY | ELI LILLY & Co | $5.8M | 4.8% | -13% | 89.3 |
| 5 | $JNJ | JOHNSON & JOHNSON | $4.5M | 3.7% | -10% | 72.8 |
| 6 | $GILD | GILEAD SCIENCES, INC. | $4.1M | 3.4% | +54% | 77.8 |
| 7 | $UNH | UNITEDHEALTH GROUP INC | $4.0M | 3.4% | +10% | 66.8 |
| 8 | $AMGN | AMGEN INC | $3.5M | 2.9% | -30% | 79.5 |
| 9 | $VRTX | VERTEX PHARMACEUTICALS INC / MA | $3.5M | 2.9% | -12% | 76.6 |
| 10 | $INSM | INSMED Inc | $3.4M | 2.8% | +76% | 29.4 |
| 11 |  $ARGX | ARGENX SE | $2.7M | 2.3% | +23% | — |
| 12 |  $ABBV | AbbVie Inc. | $2.7M | 2.2% | -27% | 59.3 |
| 13 |  $ABT | ABBOTT LABORATORIES | $2.6M | 2.2% | +9% | 67 |
| 14 |  $MRK | Merck & Co., Inc. | $2.6M | 2.1% | +0% | 70.9 |
| 15 |  $REGN | REGENERON PHARMACEUTICALS, INC. | $2.5M | 2.1% | -21% | 75.1 |
| 16 |  $ISRG | INTUITIVE SURGICAL INC | $2.4M | 2.0% | +8% | 81.4 |
| 17 |  $BSX | BOSTON SCIENTIFIC CORP | $2.2M | 1.8% | +26% | 79.9 |
| 18 |  $BNTX | BioNTech SE | $2.0M | 1.7% | +29% | — |
| 19 |  $SYK | STRYKER CORP | $1.9M | 1.6% | -10% | 69.8 |
| 20 |  $DHR | DANAHER CORP /DE/ | $1.8M | 1.5% | -9% | 63.9 |
| 21 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $1.7M | 1.4% | -10% | 63.7 |
| 22 |  $DXCM | DEXCOM INC | $1.5M | 1.2% | -19% | 77.9 |
| 23 |  $IQV | IQVIA HOLDINGS INC. | $1.4M | 1.2% | NEW | 59.7 |
| 24 |  $SMMT | Summit Therapeutics Inc. | $1.4M | 1.2% | -13% | — |
| 25 |  $EW | Edwards Lifesciences Corp | $1.4M | 1.1% | +1% | 67.6 |
| 26 |  $BMY | BRISTOL MYERS SQUIBB CO | $1.3M | 1.1% | NEW | 70.1 |
| 27 |  $UTHR | UNITED THERAPEUTICS Corp | $1.1M | 0.9% | -1% | 80.1 |
| 28 |  $VERA | Vera Therapeutics, Inc. | $1.1M | 0.9% | -31% | — |
| 29 |  $RCUS | Arcus Biosciences, Inc. | $1.0M | 0.9% | -21% | 12 |
| 30 |  $ROIV | Roivant Sciences Ltd. | $1.0M | 0.8% | -28% | — |
| 31 |  $MDT | Medtronic plc | $961,815 | 0.8% | NEW | — |
| 32 |  $TRVI | Trevi Therapeutics, Inc. | $939,499 | 0.8% | -12% | — |
| 33 |  $COGT | Cogent Biosciences, Inc. | $902,398 | 0.8% | -32% | — |
| 34 |  $MLYS | Mineralys Therapeutics, Inc. | $895,135 | 0.7% | -0% | — |
| 35 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $864,232 | 0.7% | -23% | 60.9 |
| 36 |  $TARS | Tarsus Pharmaceuticals, Inc. | $852,463 | 0.7% | -24% | 40.8 |
| 37 |  $RAPP | Rapport Therapeutics, Inc. | $835,005 | 0.7% | -35% | — |
| 38 |  $NKTR | NEKTAR THERAPEUTICS | $820,662 | 0.7% | -20% | 10.2 |
| 39 |  $SNDX | Syndax Pharmaceuticals Inc | $787,466 | 0.7% | -48% | 30 |
| 40 |  $ARDX | ARDELYX, INC. | $781,060 | 0.7% | NEW | 35.3 |
| 41 |  $PFE | PFIZER INC | $772,200 | 0.6% | +1% | 69 |
| 42 |  $BOLD | Boundless Bio, Inc. | $746,431 | 0.6% | +0% | — |
| 43 |  $ASND | Ascendis Pharma A/S | $728,276 | 0.6% | -14% | 41.5 |
| 44 |  $AVBP | ArriVent BioPharma, Inc. | $720,430 | 0.6% | -22% | — |
| 45 |  $GPCR | Structure Therapeutics Inc. | $710,805 | 0.6% | -41% | — |
| 46 |  $IMTX | Immatics N.V. | $692,687 | 0.6% | +6% | — |
| 47 |  $BBIO | BridgeBio Pharma, Inc. | $687,276 | 0.6% | -27% | 31.7 |
| 48 |  $SPRY | ARS Pharmaceuticals, Inc. | $676,672 | 0.6% | +166% | 29.7 |
| 49 |  $ONC | BeOne Medicines Ltd. | $631,061 | 0.5% | -30% | — |
| 50 |  $TECX | Tectonic Therapeutic, Inc. | $628,215 | 0.5% | -55% | — |
| 51 |  $IONS | IONIS PHARMACEUTICALS INC | $617,240 | 0.5% | -14% | 37.1 |
| 52 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $607,268 | 0.5% | -13% | 74.1 |
| 53 |  $KURA | Kura Oncology, Inc. | $606,010 | 0.5% | +32% | 9.1 |
| 54 |  $PRVA | Privia Health Group, Inc. | $558,188 | 0.5% | +4% | 49.4 |
| 55 |  $CYTK | CYTOKINETICS INC | $544,614 | 0.5% | +24% | 28 |
| 56 |  $PTCT | PTC THERAPEUTICS, INC. | $515,063 | 0.4% | -14% | 80 |
| 57 |  $QURE | uniQure N.V. | $499,411 | 0.4% | -4% | — |
| 58 |  $AGMB | Agomab Therapeutics NV | $477,295 | 0.4% | NEW | — |
| 59 |  $ALHC | Alignment Healthcare, Inc. | $474,172 | 0.4% | -15% | 63 |
| 60 |  $HNGE | Hinge Health, Inc. | $472,129 | 0.4% | -14% | 44.9 |
| 61 |  $RDNT | RadNet, Inc. | $447,064 | 0.4% | -27% | 51.4 |
| 62 |  $RPRX | Royalty Pharma plc | $393,834 | 0.3% | -15% | — |
| 63 |  $BIIB | BIOGEN INC. | $385,910 | 0.3% | -14% | 65.6 |
| 64 |  $INSP | Inspire Medical Systems, Inc. | $372,666 | 0.3% | +0% | 46 |
| 65 |  $JAZZ | Jazz Pharmaceuticals plc | $371,294 | 0.3% | -15% | — |
| 66 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $343,841 | 0.3% | -14% | 75.4 |
| 67 |  $ORIC | Oric Pharmaceuticals, Inc. | $332,651 | 0.3% | +5% | — |
| 68 |  $OMDA | Omada Health, Inc. | $322,043 | 0.3% | -30% | 45.5 |
| 69 |  $ABVX | Abivax S.A. | $297,861 | 0.3% | NEW | — |
| 70 |  $ILMN | ILLUMINA, INC. | $296,071 | 0.3% | -14% | 62.5 |
| 71 |  $AXSM | Axsome Therapeutics, Inc. | $289,869 | 0.2% | -14% | 36.6 |
| 72 |  $INCY | INCYTE CORP | $254,124 | 0.2% | -15% | 81.2 |
| 73 |  $MRNA | Moderna, Inc. | $247,904 | 0.2% | -13% | 15.9 |
| 74 |  $MEDP | Medpace Holdings, Inc. | $228,090 | 0.2% | NEW | 77.4 |
| 75 |  $GH | Guardant Health, Inc. | $205,523 | 0.2% | NEW | 36.1 |
| 76 |  $RVMD | Revolution Medicines, Inc. | $202,280 | 0.2% | NEW | — |
| 77 |  $PALI | PALISADE BIO, INC. | $172,375 | 0.1% | NEW | — |
New Positions (10)
$IQV IQVIA HOLDINGS INC.$1.4M$BMY BRISTOL MYERS SQUIBB CO$1.3M$MDT Medtronic plc$961,815$ARDX ARDELYX, INC.$781,060$AGMB Agomab Therapeutics NV$477,295$ABVX Abivax S.A.$297,861$MEDP Medpace Holdings, Inc.$228,090$GH Guardant Health, Inc.$205,523$RVMD Revolution Medicines, Inc.$202,280$PALI PALISADE BIO, INC.$172,375
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for SECTORAL ASSET MANAGEMENT INC including:
Track SECTORAL ASSET MANAGEMENT INC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for SECTORAL ASSET MANAGEMENT INC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: SECTORAL ASSET MANAGEMENT INC
13F Pro is an AI hedge fund tracker and stock research platform. For SECTORAL ASSET MANAGEMENT INC (SEC CIK: 1274413), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in SECTORAL ASSET MANAGEMENT INC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.